This study’s principal finding was that COL4A6 played an important role in the regulation of cell aggressiveness, cell proliferation, tumor formation, and chemoresistance and that COL4A6 expression acted as a predictor of poor clinical outcomes in patients with EOC. This evidence concerns the gene COL4A6 and neoplasm.